Fundraising FoxSV Health Investors — 2025 Investments
7 investments dated 2025 · listed companies and verified rows first · show all
Alchemab operates a platform that identifies novel drug targets and therapeutics by analyzing patient antibody repertoires using deep B cell sequencing and computational analysis of samples from disease-resilient individuals.
AI & Machine LearningBiotechDeep TechHealthtech
Jane Osbourn(Founder)Young Kwon(Founder)
Co-investorsRA CapitalDCVC BioDementia Discovery FundLightstone VenturesOno Venture Investment, Inc.British Business Bank+3 more
Dualitas Therapeutics develops bispecific antibody therapies that pair a proprietary proximity engager arm with an antibody against a therapeutic target, using its DualScreen discovery engine to identify synergistic target combinations.
BiotechDeep TechSouth San Francisco, US
Greg Lazar, Ph.D.(Co-Founder and Chief Scientific Officer)Forbes Huang(Co-Founder, Chief Operating Officer & Chief Business Officer)inGreg Lazar(Co-Founder & Chief Scientific Officer)inRichard Murray(Executive Officer, Director)Karim Dabbagh(Chief Executive Officer, Board Member)in
BoardAlicia Levey(Director)
Co-investorsQiming Venture PartnersVersant VenturesAlexandriaDementia Discovery FundQiming HealthcareQiming Venture Partners USA
Developer of a transcatheter InterAtrial Shunt Device to treat congestive heart failure.
BiotechTewksbury, US
George J. Fazio(Executive Officer, Director)inDan B. Curtis(Executive Officer)
BoardKevin Gillis(Director)inGerald Brunk(Director)inIrit Yaniv(Director)in
Board seatPaul LaViolette· per SEC Form D · $11.1M raise · filed Jun 2025
Co-investorsAccelmed PartnersLumira VenturesGeneral CatalystThird Rock Ventures
.png)
Lunair Medical develops an implantable closed-loop system that senses respiration and stimulates the phrenic nerve to treat moderate-to-severe sleep apnea, avoiding masks, mouthpieces, and wearables.
Digital HealthHealthtechMedical DevicesMinneapolis, US
Mark Christopherson(Executive Officer, Director)inHoward Levin(Director)
BoardDavid Neustaedter(Director)inMichael Hurley(Director)
Board seatPaul LaViolette· per SEC Form D
Artios develops DNA damage response (DDR)-based medicines targeting patients with high unmet need cancers.
BiotechHealthtechMedical Devices
Co-investorsAndera PartnersDementia Discovery FundM VenturesNovartis Venture FundPfizer Venture InvestmentsRA Capital+6 more
Imbria Pharmaceuticals develops novel cardiovascular disease treatments that target cardiac energy metabolism, with a lead drug candidate, ninerafaxstat, in clinical trials for non-obstructive hypertrophic cardiomyopathy.
BiotechDigital Health
Alvin Shih(CEO)inAlbert M. Kim(Chief Medical Officer)in
Co-investorsAN Venture PartnersCatalio Capital Management, LPRA CapitalSanofi VenturesCatalio Capital Management
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.